olaparib,bevacizumab
roche,astrazeneca,merck
['bevacizumab', 'vance', 'brca', 'ovarian', 'paola-1', 'medsir']
great talk by dr. about paola-1 trial. maintenance therapy with olaparip plus bevacizumab in pts with newly diagnosed advanced ovarian cancer, resulted in a significant improvement in os in hdr-positive patients (regardless brca mutation status). #esmo2022 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM